MedTrace Logo

A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis

NCT05382819 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2023-08-24

No results posted yet for this study

Summary

FRTX-02 is an orally-available, potent and selective DYRK1A inhibitor.

Conditions

  • Atopic Dermatitis Eczema

Interventions

DRUG

FRTX-02 Capsule

DYRK-1A Inhibitor

DRUG

Placebo

Matching Placebo

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • Innovaderm Research Inc.

    collaborator OTHER

  • Fresh Tracks Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-16
Primary Completion
2023-02-08
Completion
2023-08-11

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05382819 on ClinicalTrials.gov